Dyclonine

NexMed, Inc. (NASDAQ: NEXM), a developer of innovative treatments based on the NexACT® drug delivery technology, today announced that Dr. Marc Gittelman, MD, FACS, Director of the Miami Center for Sexual Health and a NexMed consultant, will make four presentations at the 8th Annual Meeting of the European Society for Sexual Medicine ("ESSM"), which takes place December 4-7, 2005 in Copenhagen, Denmark. Dr. Gittelman's presentations will include data on NM100061, NexMed's proprietary early ejaculation ("EE") treatment under development. EE, commonly known as premature ejaculation, is the most prevalent male sexual dysfunction, affecting as many as one-third of men worldwide at some time in their lives. Unlike Johnson and Johnson's Dapoxetine, an oral treatment under development, NM100061 is applied locally.

Dr. Gittelman's four presentations are titled:

Copies of the abstracts are available through NexMed.

About NexMed, Inc.

NexMed, Inc. is an emerging drug developer that is leveraging its proprietary drug technology to develop a significant pipeline of innovative pharmaceutical products to address significant unmet medical needs. The Company is also working with various pharmaceutical companies to explore the incorporation of NexACT into their existing drugs as a means of developing new patient-friendly transdermal products and extending patent lifespans and brand equity.

Contacts: Deborah Carty NexMed, Inc. (609) 208-9688, ext: 159 Email Contact Media: Marni Kotak Excite Media Group (212) 941-8499 x102 Email Contact